Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label Mavyret (glecaprevir/pibrentasvir). Show all posts
Showing posts with label Mavyret (glecaprevir/pibrentasvir). Show all posts
Thursday, February 21, 2019

MAVIRET - AbbVie reaches an agreement with the pan-Canadian For HCV Drug

›
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for its hepatitis C treatment MAVIRET™ Feb. 21, 2019, 1...
Saturday, February 9, 2019

Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6

›
Int J Drug Policy. 2019 Feb 5;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. [Epub ahead of print] Safety and efficacy of glecaprevir/pib...
Wednesday, January 2, 2019

Hepatitis C: Mavyret (glecaprevir/pibrentasvir) in patients aged 65 years or older

›
Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older Graham R. Fos...
Tuesday, November 20, 2018

Mavyret for HCV/HIV Coinfection and Genotype 3: A Report of Three Cases

›
Intern Med. 2018 Nov 19. doi: 10.2169/internalmedicine.1856-18. [Epub ahead of print] Glecaprevir and Pibrentasvir for Japanese Patients...
Tuesday, November 13, 2018

8-week Maviret HCV genotype 1-6 & compensated cirrhosis:The EXPEDITION-8 Study

›
Meeting Coverage @ infohep 8 weeks of Maviret cures 98% of people with hepatitis C and cirrhosis Keith Alcorn / 14 November 2018 An 8-wee...

AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

›
The Liver Meeting® 2018 Meeting Updates  View all updates on this blog, ( LINK ), coverage elsewhere, (LINK ). Related Links: High S...
Monday, November 12, 2018

The Medicines Patent Pool Signs Licence With AbbVie to Expand Access to Key Hepatitis C Treatment, glecaprevir/pibrentasvir

›
The Medicines Patent Pool Signs Licence With AbbVie to Expand Access to Key Hepatitis C Treatment, glecaprevir/pibrentasvir  SAN FRANCIS...

High SVR12 rate for 16 week glecaprevir/pibrentasvir regimen in HCV GT1

›
Combo HCV Pill Effective in Certain Refractory Patients High SVR12 rate for 16 week glecaprevir/pibrentasvir regimen in HCV GT1 patients ...
Saturday, November 10, 2018

The Liver Meeting® - Combined Glecaprevir/Pibrentasvir Highly Effective in HCV Patients Who Have Failed Other Therapies

›
Combined Glecaprevir and Pibrentasvir Found Highly Effective in Chronic Hepatitis C Patients Who Have Failed Other Therapies SAN FRANCISCO...
Monday, October 29, 2018

Mavyret (glecaprevir/pibrentasvir) 8 Wks Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function

›
Infect Dis Ther. 2018 Oct 27. doi: 10.1007/s40121-018-0218-x. [Epub ahead of print] Pan-Genotypic Hepatitis C Treatment with Glecaprevir a...
Thursday, August 9, 2018

FDA: Hepatitis C Drug Labeling Updated to Include New Clinical Data

›
Pharmacy Times FDA: Hepatitis C Drug Labeling Updated to Include New Clinical Data The FDA has approved updates to the labeling for hep...
Thursday, July 12, 2018

Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection

›
Journal of Hepatology Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection JohannesVermehren...
Wednesday, June 13, 2018

High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

›
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis ...
Friday, April 13, 2018

First real-world data on Mavyret showing safety & effectiveness in HCV Genotype 1-6

›
Shared on Twitter today by @HenryEChang - First real-world data from the Deutsches Hepatitis C-Register (DHC-R) showing favorable safety ...
Thursday, April 12, 2018

Liver Congress™ 2018 First real-world studies report glecaprevir/pibrentasvir to be effective and well tolerated in chronic HCV infection

›
Related: Real-world experience confirms Mavyret efficacy in HCV April 12, 2018 PARIS — Two real-world studies presented at the Internationa...
Tuesday, February 6, 2018

AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™

›
AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™ - an oral therapy for the treatment of...
Sunday, January 28, 2018

HCV Updates & A Look At The Most Intense Flu Season In Years

›
Welcome, sit back and catch up on notable research articles and blog updates on the topic of viral hepatitis. However, we begin with upda...